ZIVO Bioscience (ZIVO) Competitors $11.75 -0.28 (-2.33%) As of 10/3/2025 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ZIVO vs. HRTX, AVIR, PRQR, SGMT, TRDA, CABA, TNXP, VTYX, CRBU, and BDTXShould you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include Heron Therapeutics (HRTX), Atea Pharmaceuticals (AVIR), ProQR Therapeutics (PRQR), Sagimet Biosciences (SGMT), Entrada Therapeutics (TRDA), Cabaletta Bio (CABA), Tonix Pharmaceuticals (TNXP), Ventyx Biosciences (VTYX), Caribou Biosciences (CRBU), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry. ZIVO Bioscience vs. Its Competitors Heron Therapeutics Atea Pharmaceuticals ProQR Therapeutics Sagimet Biosciences Entrada Therapeutics Cabaletta Bio Tonix Pharmaceuticals Ventyx Biosciences Caribou Biosciences Black Diamond Therapeutics Heron Therapeutics (NASDAQ:HRTX) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability. Do insiders and institutionals believe in HRTX or ZIVO? 80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 5.9% of Heron Therapeutics shares are held by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is HRTX or ZIVO more profitable? ZIVO Bioscience has a net margin of 0.00% compared to Heron Therapeutics' net margin of -0.62%. Company Net Margins Return on Equity Return on Assets Heron Therapeutics-0.62% N/A -0.40% ZIVO Bioscience N/A N/A -2,240.92% Which has stronger earnings & valuation, HRTX or ZIVO? ZIVO Bioscience has lower revenue, but higher earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHeron Therapeutics$144.29M1.68-$13.58M-$0.02-66.00ZIVO Bioscience$15.85K2,829.64-$7.78M-$2.58-4.55 Which has more risk & volatility, HRTX or ZIVO? Heron Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500. Does the media refer more to HRTX or ZIVO? In the previous week, Heron Therapeutics' average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score. Company Overall Sentiment Heron Therapeutics Neutral ZIVO Bioscience Neutral Do analysts recommend HRTX or ZIVO? Heron Therapeutics currently has a consensus price target of $4.50, suggesting a potential upside of 240.91%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Heron Therapeutics is more favorable than ZIVO Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heron Therapeutics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryHeron Therapeutics beats ZIVO Bioscience on 8 of the 13 factors compared between the two stocks. Get ZIVO Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZIVO vs. The Competition Export to ExcelMetricZIVO BioscienceBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.85M$354.45M$6.10B$10.53BDividend YieldN/AN/A5.51%4.67%P/E Ratio-2.41N/A85.6826.86Price / Sales2,829.64436.13582.47185.05Price / CashN/A22.4426.3031.10Price / Book-14.513.8513.246.72Net Income-$7.78M-$133.30M$3.30B$276.35M7 Day Performance-26.52%5.43%4.67%3.10%1 Month Performance-20.88%21.23%8.40%10.19%1 Year Performance-38.71%19.48%88.01%40.34% ZIVO Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZIVOZIVO Bioscience0.1371 of 5 stars$11.75-2.3%N/A-37.4%$44.85M$15.85K-2.4110Gap UpHRTXHeron Therapeutics3.552 of 5 stars$1.26-0.8%$4.50+257.1%-36.8%$232.81M$144.29M-63.00300AVIRAtea Pharmaceuticals1.4387 of 5 stars$2.90-0.7%$6.00+106.9%-15.9%$231.72MN/A-1.8070News CoveragePositive NewsPRQRProQR Therapeutics2.3597 of 5 stars$2.13-2.7%$8.00+275.6%+21.0%$230.41M$20.46M-4.63180Positive NewsSGMTSagimet Biosciences2.8331 of 5 stars$6.86-0.9%$25.67+274.1%+78.7%$225.05M$2M-3.758News CoverageTRDAEntrada Therapeutics3.1432 of 5 stars$5.80-0.7%$25.67+342.5%-65.3%$222.14M$210.78M-3.26110CABACabaletta Bio2.2573 of 5 stars$2.34-1.7%$14.50+519.7%-42.7%$217.69MN/A-0.8650TNXPTonix Pharmaceuticals2.7924 of 5 stars$24.16-2.4%$70.00+189.7%+73.7%$217.04M$10.09M-0.6150VTYXVentyx Biosciences1.6726 of 5 stars$3.11+2.6%$7.50+141.2%+77.6%$215.71MN/A-1.8530CRBUCaribou Biosciences1.8994 of 5 stars$2.33+1.3%$6.67+186.1%+25.1%$214.18M$9.99M-1.31100BDTXBlack Diamond Therapeutics3.5161 of 5 stars$3.79+1.6%$11.00+190.2%+4.5%$212.37MN/A16.4890Positive News Related Companies and Tools Related Companies HRTX Alternatives AVIR Alternatives PRQR Alternatives SGMT Alternatives TRDA Alternatives CABA Alternatives TNXP Alternatives VTYX Alternatives CRBU Alternatives BDTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZIVO) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZIVO Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZIVO Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
